Employees: 186
Size Pharmicell (005690.KS) is a South Korea Health Care company (Pharmaceuticals: Major) with a market value of $364M, the 429th largest of 483 South Korea companies the cockpit tracks. Shares closed at ₩8,240 on 18 Nov 2026.
Performance Over six months the shares fell 54.7%, against -22.6% for the median peer and -37.2% for the South Korea market (cap-weighted) — 3rd lowest of 19 in its peer set.
Growth Revenue grew 45.9% over the last twelve months (peer median -6.5%); the operating margin is 32.2% (peer median -13.0%).
Valuation It trades at 8.2× forward earnings against a peer median of 27.2× (cheapest of 5).
Price implies For today's price to make sense, revenue must grow about -8% a year for seven years (Req g). Recent delivered growth is +25%, so the hurdle is -33 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 26.7 points above its cost of capital (6.7% WACC).
Next results Next results expected around 24 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₩147B | ₩114B | ₩64.9B | ₩56.2B | ₩60.2B |
| Revenue growth | — | +76% | +15% | -7% | — |
| Gross profit | ₩64.8B | ₩50.0B | ₩20.6B | ₩15.0B | ₩23.3B |
| EBITDA | ₩50.3B | ₩36.8B | ₩7.24B | ₩3.79B | ₩10.3B |
| Net income | ₩46.0B | ₩40.3B | ₩6.33B | ₩3.58B | ₩8.26B |
| Free cash flow | ₩28.1B | ₩33.6B | -₩780M | ₩5.80B | -₩11.0B |
| Capital expenditure | ₩20.7B | ₩7.49B | ₩4.34B | ₩6.02B | ₩19.0B |
| Total debt | ₩30.0B | ₩14.6B | ₩686M | ₩3.03B | ₩16.8B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 005690.KS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -21.8% | -12.7% | 2nd lowest of 20 |
| 6-month return | -54.7% | -22.6% | 3rd lowest of 19 |
| Distance from 52-week high | -61.0% | -38.5% | 6th lowest of 21 |
| Revenue growth (TTM) | +45.9% | -6.5% | 2nd highest of 18 |
| Operating margin | 32.2% | -13.0% | 2nd highest of 18 |
| Forward P/E | 8.2× | 27.2× | cheapest of 5 |
| Growth the price implies (Req g, 7 yrs) | -7.9% | 7.3% | least demanding of 7 |
| Growth delivered (Del g) | +24.8% | +1.7% | 2nd highest of 7 |
| Hurdle (Req g minus delivered) | -32.6 pp | +1.5 pp | least demanding of 7 |
| ROIC minus cost of capital | +26.7 pp | -7.2 pp | 2nd highest of 16 |
| EV / EBITDA | 8.7× | 15.7× | 3rd cheapest of 6 |
| Net debt / EBITDA | -0.9× | 0.2× | 2nd least indebted of 6 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Pharmicell 005690.KS | South Korea | $364M | -55% | +46% | 32% | 8.2× | -7.9% | +24.8% |
| Tuoxin Pharmaceutical 301089.SZ | China | $363M | -28% | +17% | -20% | n/a | n/a | n/a |
| Unichem Laboratories UNICHEMLAB.NS | India | $361M | +28% | +6% | 5% | n/a | n/a | n/a |
| Guangdong Lifestrong Pharmacy 301111.SZ | China | $368M | -33% | +7% | -2% | n/a | n/a | n/a |
| 6467 6467.TW | Taiwan | $368M | n/a | n/a | -2,618% | n/a | n/a | n/a |
| KYORIN Pharmaceutical 4569.T | Japan | $360M | -22% | -6% | 2% | 35.5× | 6.7% | +4.2% |
| MapLight Therapeutics MPLT | United States | $370M | -76% | n/a | n/a | n/a | n/a | n/a |
| Tiansheng Pharmaceutical 002872.SZ | China | $371M | -1% | -1% | -13% | n/a | 22.2% | -15.7% |
| ARS Pharmaceuticals SPRY | United States | $371M | -53% | -14% | -162% | n/a | n/a | n/a |
| Puma Biotechnology PBYI | United States | $373M | +3% | +9% | 11% | 19.0× | 0.1% | +0.3% |
| Anhui Fengyuan Pharmaceutical 000153.SZ | China | $355M | -17% | -24% | 3% | n/a | 3.6% | +3.1% |
| Jiangsu Bioperfectus Technologies 688399.SS | China | $374M | -51% | -8% | -23% | n/a | n/a | n/a |
| ASKA Pharmaceutical 4886.T | Japan | $354M | -24% | +11% | n/a | 12.9× | n/a | n/a |
| Guizhou Yibai Pharmaceutical 600594.SS | China | $351M | -23% | -26% | -15% | n/a | 8.0% | -11.3% |
| Opus Genetics IRD | United States | $379M | -22% | -46% | -778% | n/a | n/a | n/a |
| JCR Pharmaceuticals 4552.T | Japan | $379M | -5% | +3% | -14% | 398.3× | n/a | n/a |
| Lifecome Biochemistry 002868.SZ | China | $384M | -54% | -23% | -3% | n/a | n/a | n/a |
| SanBio 4592.T | Japan | $386M | -55% | n/a | n/a | n/a | n/a | n/a |
| Gansu Longshenrongfa Pharmaceutical Industry 300534.SZ | China | $386M | -2% | -21% | 8% | n/a | 20.9% | +28.2% |
| Shukra Pharmaceuticals SHUKRAPHAR.NS | India | $387M | n/a | +222% | 54% | n/a | n/a | n/a |
| iX Biopharma 42C.SI | Singapore | $387M | +28% | -12% | -140% | n/a | n/a | n/a |